Biosimilar Contract Manufacturing Market Size, Share & Trends Analysis Report By Production Technology (Mammalian, Non-Mammalian), By Region, And Segment Forecasts, 2022 To 2030

The global biosimilar contract manufacturing market is expected to register significant growth during the forecast period. A considerable market has been formed for contract development and manufacturing organizations (CDMOs) offering outsourced services because of the rapid growth in the number of companies engaged in the development and registration of biosimilars. When they lack the internal capacity, ability to carry out a specific task, or when they need more resources to launch products quickly, biosimilar developers turn to contract development and manufacturing companies.

Mammalian holds the highest market share by production technology owing to a large percentage of biosimilar products that are in pipeline.

Europe holds a notable share in the biosimilar contract manufacturing market owing to the presence of multiple service providers in terms of offering biosimilar contract manufacturing.

Small, newly formed biotech companies creating their first products, as well as big pharma companies lacking knowledge in the development of a biologic drug, but recognizing the profits generated by the biosimilar market are the most likely customers for biosimilar contract development and manufacturing service providers (CDMOs). Contract development and manufacturing services demand may rise as producers of the first biosimilars presented in emerging markets without rigid approval processes constitute to upgrade their products to compete in major established markets.

The number of investments in biopharmaceutical contract development and manufacturing space has increased as more biosimilars and innovative drugs enter the market. There is a need for additional capacity, and the regulatory policy is shifting. For instance, in August 2021, Samsung Biologics announced that it plans to invest USD 205 billion and hire more people to increase CDMO, biosimilars, and other things in the coming years. It will benefit several Samsung businesses, including Samsung Bioepis, which deals with biosimilars, and Samsung Biologics, which handles contract manufacturing.

The key global industry players across the market include Eurofins Scientific, SGS SA, Charles River Laboratories, Intertek Group Plc, Labcorp Drug Development, Medpace, and a few others.